Q1 2026 Trading Update

AI SummaryClose X

Shield Therapeutics plc reported unaudited Q1 2026 Group net revenues of $18 million, with ACCRUFeR® net revenue growing 54% year-on-year to $9.9 million, contributing to a positive EBIT of approximately $2.5 million. The company also announced a CFO transition, with CEO Anders Lundstrom stepping in as interim CFO while a permanent successor is sought. Despite new Prior Authorisation requirements impacting sales in New York's Medicaid program, Shield is pivoting sales efforts to commercial plans. Cash reserves increased to $12.4 million, and regulatory progress includes the acceptance of the ACCRUFeR® Marketing Authorisation Application in China and an EMA approval for FeRACCRU® in children over 12.

Disclaimer*

UK 100

Latest directors dealings